Document is current
Any future updates will be listed below
-
Authors
Rao, Anika
Lowe, Michael https://orcid.org/0000-0001-5712-3800
Sinclair, Alex https://orcid.org/0000-0003-2777-5132
Mollan, Susan P. https://orcid.org/0000-0002-6314-4437
Berman, Gabriele https://orcid.org/0009-0008-3390-9508
- License Information
-
More Information
Article History
Received: 13 July 2025
Revised: 30 July 2025
Accepted: 27 August 2025
First Online: 15 October 2025
Competing interests
: ML reports speaker fees (Pfizer); travel (AbbVie, Teva, Lundbeck). AS reports has consulted for Novartis, AbbVie, Vertex and Orion Pharma and speaker fees from Teva UK and Novartis. She was previously a Director and Chief Scientific Officer (CSO) with shares at Invex Therapeutics. SM reports consultancy fees (Invex Therapeutics); advisory board fees (Ocular Therapeutix); speaker fees (Teva); travel (AbbVie and European Alliance of Associations for Rheumatology); Receipt of equipment (Heidelberg Engineering). SM is a section editor at Eye Journal. Authors declare no other financial relationships with any organisations that might have an interest in the submitted work, and no other relationships or activities that could appear to have influenced the submitted work.
